Dane Leone
Stock Analyst at Raymond James
(1.18)
# 3,782
Out of 5,105 analysts
69
Total ratings
33.96%
Success rate
-6.76%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $29 → $19 | $7.79 | +143.90% | 3 | Aug 8, 2025 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.71 | +463.14% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $12.85 | +250.19% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $78.51 | -61.79% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $746.80 | +27.21% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $1.87 | +595.19% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $74.07 | -37.89% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $32.57 | +111.85% | 5 | May 8, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $5.39 | +48.42% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $14.67 | -4.57% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $17.05 | +240.18% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $19.51 | +258.79% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.55 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $60.77 | +3.67% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $51.20 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.29 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $81.75 | -20.49% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $317.38 | -19.65% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $4.41 | +626.45% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $210.01 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $19
Current: $7.79
Upside: +143.90%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.71
Upside: +463.14%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $12.85
Upside: +250.19%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $78.51
Upside: -61.79%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $746.80
Upside: +27.21%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $1.87
Upside: +595.19%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $74.07
Upside: -37.89%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $32.57
Upside: +111.85%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $5.39
Upside: +48.42%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $14.67
Upside: -4.57%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $17.05
Upside: +240.18%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $19.51
Upside: +258.79%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.55
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $60.77
Upside: +3.67%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $51.20
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.29
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $81.75
Upside: -20.49%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $317.38
Upside: -19.65%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $4.41
Upside: +626.45%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $210.01
Upside: -